New combo therapy targets Hard-to-Treat head and neck cancers
NCT ID NCT00494182
First seen Nov 10, 2025 · Last updated May 07, 2026 · Updated 22 times
Summary
This study tests whether adding the drug sorafenib to standard chemotherapy (carboplatin and paclitaxel) can help control advanced head and neck cancer that has spread or returned. About 48 adults with this type of cancer will receive the combination treatment. The goal is to see how well the tumors shrink or stop growing, and to track how long patients stay progression-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.